Loading
A phase 3 trial of Lurbinectedin and Doxorubicin in uterine sarcoma, run by PharmaMar, active and no longer recruiting.
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) is a phase 3 interventional study registered as NCT06088290 by PharmaMar, with 469 participants enrolled, started 2023-09-21 and due to reach its primary completion in 2029-08-30. Interventions recorded: Lurbinectedin and Doxorubicin.
Shares PharmaMar and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares PharmaMar and the tag pipeline.
Shares PharmaMar and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.